21. A Simple and Effective Chemical Phosphorylation Procedure for Biomolecules

by **Willi Bannwarth*** and **Arnold Trzeciak**

F. Hoffmann-La Roche & Co., Ltd., Central Research Units, CH-4002 Basel

(Y.Xl1.86)

A general chemical phosphorylation method based on P(II1) chemistry has been developed. The system is demonstrated for the phosphorylation of oligonucleotides, directly after their synthesis on a solid support, and for the 0-phosphorylation of serine, threonine, and tyrosine as well as for a serine-containing peptide.

1. Introduction. - Many natural products exist as their phosphoric-acid esters. For their chemical synthesis, the phosphate moiety is mainly introduced *via* protected phosphoric-acid derivatives. The protecting groups should be stable during the phosphorylation procedure but should be cleaved selectively and quantitatively afterwards to yield the desired phosphorylated species. There exists a number of phosphate-protecting groups, but only a few of them seem to be of general applicability. We would like to report a very effective phosphorylation system which can be applied under very mild conditions and which is based on P(II1) chemistry. It allows to use different protecting groups and, thus, to adapt them to the compound to be phosphorylated.

There are several reports on the synthesis of different alkoxybis(dialky1amino) phosphines **2** [l-41. They are easily prepared from PC1, *(Scheme 1)* which is reacted first with an alcohol to give the alkoxydichlorophosphine **1.** Further reaction of these compounds yields then the corresponding **alkoxybis(dialky1amino)phosphines 2.** Compounds 2 are quite stable and easy to handle. They show a strong $p_x - d_x$ interaction of the N-atom of the dialkylamino functions with the P-atom *[5].* This makes them easily susceptible for a protonation with very weak acids leading to an activated species which can react with another alcohol (R'OH) to the **dialkoxy(dialky1amino)phosphines 3.** The newly introduced alkoxy function reduces the $p_{\pi} - d_{\pi}$ interaction, and, therefore, compounds of type **3** are less susceptible for protonation (activation), and thus, compounds of type **3** behave like monofunctional reagents. Nevertheless, compounds of type **3** can still be activated under slightly more acidic conditions and allow their reaction with a

further alcohol or substrate bearing a suitable OH function (R^3OH) to yield a phosphite triester **4.** Oxidation of **4** leads to the corresponding phospho triesters *5,* and selective cleavage of $R¹$ and $R²$ gives, finally, the phosphorylated compound **6**.

The intermediate **dialkoxy(dialky1amino)phosphines 3** can be prepared very easily in high yields, and they are stable compounds, sometimes as stable as to allow their purification by silica-gel chromatography. Thus, they can be stored for a long time without decomposition in contrast to the corresponding dialkoxychlorophosphines sometimes used for phosphinylation *[6].* Since the following steps (reaction of dialkoxy- (dialky1amino)phosphines with an alcohol and oxidation) proceed also in very high yields and under very mild conditions, this phosphorylation procedure should be of general use. The protecting groups can be adapted to the molecules to be phosphorylated.

2. Results and Discussion. - 2.1. *Phosphinylation Reagents.* To evaluate different phosphinylation reagents, we have synthesized the **alkoxybis(dialky1amino)phosphines 2a** and **2b** and the **dialkoxy(dialky1amino)phosphines 3a-c** *(Scheme 2).* Thereby, we concentrated mainly on possibilities of phosphorylations of biomolecules like amino acids, peptides, nucleosides, and nucleotides (DNA, RNA). As dialkylamino function, we selected for all compounds 2 and 3 the (i-Pr)₂N group. In the preparation of dichloro-(2-cyanoethoxy)phosphine **(la),** we were not able to get a good yield of distilled product (22%) due to decomposition. Therefore, the crude mixture was reacted directly with $(i-Pr)$, NH which gave, after distillation, an overall yield of 57% of pure (2-cyano**ethoxy)bis(diisopropylamino)phosphine (2a).** All the other intermediates and products could be obtained in reasonably good yields. Compounds **2a** and **b** were purified by distillation, whereas the actual phosphinylation reagents **3a**-c were so stable that they could be purified by short-column chromatography on silica gel [7].

Compounds **3a** and **b** were designed to be used mainly in connection with automated synthesis of DNA and **RNA** fragments on solid support. Most of the DNA fragments used in gene technology are used as their 5'-phosphates, and they are usually prepared by an enzymatic reaction using polynucleotide kinase and γ -³²P-ATP. A good chemical phosphorylation procedure could replace this enzymatic reaction and allow to work on a larger scale and with non-labelled DNA fragments where no radioactivity is needed *(e.g. Linker* fragments).

5a, 5b R^3 = Protected DNA fragment attached to solid support **6a** R^3 = Unprotected DNA fragment

In compound **3a,** we have combined the p-chlorobenzyl with the 2-cyanoethyl group. It can be applied to the phosphorylation of DNA fragments (R^3OH) whenever methoxy (dialky1amino)phosphoramidite building blocks were used for the synthesis of DNA on solid support **[3]** [8] *(Scheme 3).* The unprotected phosphorylated DNA fragment **6a** is then obtained by the usual deprotection procedure. The p-chlorobenzyl group of **5a** is cleaved by nucleophilic attack with thiophenol which removes at the same time the methyl groups from the internucleotide phosphate linkages. The following NH, treatment, removing the protecting groups from the exocyclic amino function of the heterocyclic bases G, A, and C and cleaving the DNA from the support, is sufficient to remove also the 2-cyanoethyl group from the phospho diester yielding then the desired 5'-phosphorylated DNA fragments (see *Chupt.* 2.2).

Compound **3b** was also designed to be used mainly in automated synthesis of phosphorylated DNA fragments, this time in combination with the more and more extensively applied (cyanoethy1)phosphoramidites [9-1 I]. After the synthesis of the phosphorylated DNA fragment on solid support **5b** *(Scheme* **3),** a single cleavage step with conc. NH, is sufficient to give directly the completely unprotected phosphorylated DNA fragment **6a** (see *Chupt.* 2.2). The cleavage of the first 2-cyanoethyl group from the phosphate moiety proceeds *via* a β -elimination, but during the cleavage of the second 2-cyanoethyl group, also an other mechanism seems to be involved [12].

The base-labile 2-cyanoethyl group can, of course, be replaced by other suitable protecting groups *(e.g. O₂NC₆H₄CH₂CH₂ [13]; CH₃SO₂CH₂CH₂ [14]; C₆H₃SO₂CH₂CH₂* $[15]$; CCl₃CH₂ $[6]$; NCCH₂C(CH₃), [16]). Furthermore, the system allows to be applied for phosphorylation of other substrates like sugars and glycerides and can also be used to link different molecules together *uia* phospho-diester bridges.

Compound **3c** was synthesized to be used in phosphorylation of amino acids like serine, threonine or tyrosine at their OH group prior or in the course of peptide synthesis, or properly protected peptides itself. There, the system offers a good alternative to the

^{&#}x27;) During the preparation of this manuscript, we realized that **3b** was also used by others for phosphorylation of **DNA** [l I].

phosphorylation by dibenzyl phosphoromonochloridate which has to be prepared in *situ* from dibenzyl phosphate and PCl, and which seems to be difficult to perform while giving rather poor yields [17-201. The benzyl protecting groups are stable under the conditions used in peptide synthesis either in solution $(N-Boc/benzyl-ester$ or $N-Z/tert- butyl-ester$ strategy) or on solid support (Boc or Fmoc strategy). They can be removed quantitatively after synthesis by catalytic hydrogenation on Pd/C without side reaction, which cleaves off at the same time the $N-Z$ and/or the benzyl-ester protection yielding directly the desired phosphorylated peptide. In order to investigate both reactions involved in the phosphorylation procedure (Scheme *1,* phosphinylation and oxidation), we have isolated and purified the phosphite triester **4a,** after phosphinylation of N- benzoyltyrosine benzyl ester with $3c$, which we were able to obtain in a range of $81-92\%$, after short-column chromatography [7] (Scheme *4).* For an evaluation of the oxidation step, **4a** was transformed to the corresponding phospho triester using different oxidation reagents (Scheme *4).* Preliminary experiments had shown that the oxidation with **1,** in THF/lutidine/H,O according to Letsinger and Lunsford [21] leads to side products when applied to intermediates of type **4** in solution (TLC). Performing this oxidation procedure with **4a** yielded **7a** in a yield of only 6%. Therefore, we were looking for alternative oxidation reagents like iodobenzene diacetate [22-241, tetrabutylammonium periodate [24] [25], m-chloroperbenzoic acid [26], peracetic acid, and tert-butyl hydroperoxide [27]. All of them gave good yields except tert-butyl hydroperoxide which yielded, after short-column chromatography, only 51 % of **7a** together with 22% of *N-* benzoyltyrosine benzyl ester. The phosphorylation can, of course, also be carried out as a one-pot procedure; thus, in the phosphorylation of *N-* benzoyltyrosine benzyl ester using *3c* for the phosphinylation and m-chloroperbenzoic acid for the oxidation, we obtained 97% of **7a.**

2.2. Phosphorylution of *DNA* Fragments on Solid Support. To demonstrate the utility of our procedure, we phosphorylated the 18-mer **DNA** fragment d(TCCCATTCCC-GAGGAGCT) according to Scheme *3.* The oligodeoxynucleotide was synthesized on controlled pore glass (CPG) as solid support using phosphoramidite chemistry [8] [28]

Reagent	Purpose	Elongation	Phosphorylation
3% Cl ₂ CHCOOH	detritylation	3 min	3 min
MeCN	wash	$4 \times$	$4 \times$
Activated amidites or phosphorylation mixture	condensation or phosphorylation	5 min	10 min
MeCN	wash	$1 \times$	1 x
Ac_2O/Me_2NPy	capping	2 min	omitted
MeCN	wash	$1 \times$	$\mathbf{1} \times$
$I2$ in THF/lutidine/H ₂ O	oxidation	2 min	2 min^a
MeCN	wash	$6 \times$	$6 \times$

Table. *Cycles for Elongation* **[33]** *and Phosphorylation*

and our standard technology [29]. A *ca.* 15-fold excess of (2-cyanoethy1)amidite [9] [lo] was applied in each elongation cycle.

The elongation cycle itself is outlined in the *Table.* After the complete synthesis of the DNA fragment, the material was splitted. One part of it was phosphorylated with **3a** and another part with **3b** by applying a standard elongation cycle with slightly longer reaction times *(Table)* and an excess of phosphinylation reagent. The resulting protected phosphorylated DNA fragments attached to the solid support, *i.e.* **5a** and **Sb,** were then treated in a different manner in order to get the desired phosphorylated fragment **6a.** Compound **5a** was first reacted with thiophenol in order to remove the p-chlorobenzyl protecting group. Afterwards it was treated with conc. NH, at 56" to cleave all other protecting groups and to remove the fragment from the solid support. In the case of **5b,** a single treatment with conc. NH₃ at 56° was sufficient to give directly the desired phosphorylated DNA fragment **6a.** The crude material of both phosphorylations was subjected, together with the unphosphorylated DNA fragment as reference, to preparative polyacrylamide gel electrophoresis *(Fig. I).* Due to the additional negative charges in the phosphorylated species, it shows a greater mobility than the parent molecule and can, therefore, be separated easily. The good performance of the phosphorylation step can be judged by the fact that no unphosphorylated DNA fragment is left *(Fig. I, lane I* and *2).*

In order to check the phosphorylated DNA fragment, it was ligated to a 25-mer DNA fragment using a 30-mer as a template by DNA ligase.

The resulting 43-mer was then labelled with $32P$ and sequenced using a modified *Maxam-Gilbert* procedure which confirmed the right sequence [30] [31].

2.3. *Phosphorylation of Amino Acids and Peptides.* a) *Amino Acids.* The introduction of a phosphate group at the OH function of the amino acids serine, threonine, and tyrosine within a peptide may have a great influence on the activity and the physical behaviour of the parent peptides.

The chemical phosphorylation itself can be either performed on the level of a properly protected peptide having the site of phosphorylation still unprotected or by using properly protected phosphorylated amino acids in the actual peptide synthesis. The second way is certainly the preferred one if the peptide to be synthesized contains amino acids giving rise to side reactions during phosphorylation, *e.g.* tryptophan and methionine in the oxidation step of the described phosphorylation procedure.

Fig. 1. *UV-shadowing gel of the S'-phosphorylated and unphosphorylated oligodeoxynucleotide d(TCCCATTCCCGAGGAGCT). Lane 1:* treatment of **5a** with thiophenol and NH,; *lane* 2: treatment of **5b** only with NH3; *lane* 3: unphosphorylated oligomer.

In order to evaluate both strategies, we have first phosphorylated protected serine, threonine, and tyrosine at their OH function according to *Scheme* **5.** In the case of tyrosine, it was especially interesting to see how well this reaction can be used for the

Scheme *6*

phosphorylation at phenolic OH functions. The phosphorylation using either reagent **3a** or **3c** was performed in a one-step fashion. The reaction proceeded in all cases in reasonably high yields and showed also a good yield when tyrosine was phosphorylated. The products were identified by spectroscopical methods.

b) Phosphorylation *of* a Peptide. **As** an example, we chose the protected pentapeptide **Boc-Asp(OBz1)-Ala-Ser-Gly-Glu(OBzl), (10)** bearing a free OH function at the Ser residue. This pentapeptide is part of the delta-sleep-inducing peptide (DSIP), and its phosphorylated form P-DSIP is ca. 10 times more active than the unphosphorylated DSIP. The phosphorylation of **10** was performed in a one-pot mode using reagent **3c** for the phosphinylation step and m-chloroperbenzoic acid for the oxidation (Scheme 6). The product **11** could be obtained after short-column chromatography in a yield of **81** %. After cleavage of the Boc protecting group at the N-terminus, we obtained **12,** and this fragment was then condensed to the tetrapeptide **13** yielding the completely protected **P-DSIP 14** in a yield of 78% (Scheme 6)²). Hydrogenation on Pd/C in AcOH gave directly the completely unprotected P-DSIP **15** which was purified by ion-exchange chromatography on *DEAE* Sephadex. *Fig.* 2 shows an HPLC of the product after cleavage of the protecting groups and after purification by ion-exchange chromatography.

3. Conclusion. - The system described is very useful for a mild and high-yield phosphorylation of OH functions in properly protected amino acids, peptides, and **DNA**

^{2,} Details of the synthesis of the building **blocks** will be reported elsewhere.

Fig. 2. *Reversed-phase HPLC of the puriJied phosphorylated Delta Sleep Inducing Peptide.* Conditions: *RP18,* 5-50% MeCN in 0.1% CF₃COOH/H₂O within 45 min, detection at 210 nm.

fragments. It can be extended to other substrates like sugars and glycerols *etc.* Work with other protecting groups is in progress.

Furthermore, by replacing one protecting group in compounds of type **3** by certain labels (fluorescing labels, spin labels), it should be possible to attach these in the same manner to biomolecules *via* phosphodiester bonds.

We would like to thank P. *Iaiza* for excellent technical assistance, *B. Hennequin* for the purification, *W. Lergier* for the HPLC and *M. Manneberg* for the quantitative determination of the amino-acid composition of the P-DSIP. Furthermore, we would like to thank our colleagues from the Central Research Units for C,H,N analysis (Dr. *A. Dirscherl),* 'H-NMR spectra (Dr. *G. Englert,* Dr. *W. Arnold),* and MS (Dr. *W. Vetter, W. Meister)* and Miss *Bächler* for typing the manuscript.

Experimental Part

1. *General.* Pyridine: refluxed and distilled from TsC1, refluxed over CaH,, distilled, and kept over molecular sieves (4Å) in tightly closed bottles. CH₂Cl₂: dried over Na₂SO₄. MeCN: refluxed over CaH₂ and distilled just prior to use. Et,O: dried over Na. Tetrazole *(Fluka)* was sublimed. Diisopropylammonium tetrazolide was prepared according to [3]. PCI₃, C₆H₃CH₂OH, p-CIC₆H₄CH₂OH, NCCH₂CH₂OH and (i-Pr)₂NH were all used without further purification. Protected amino acids were prepared according to [32]. More details about the synthesis of DNA fragments are given in [29] [33].

Short-column chromatography [7]: silica gel 60 (0.063-0.040 mm, *Merck*); solvent proportions in v/v . TLC: HPTLC-silica plates *(Merck);* compounds containing P were visualized on **TLC** by *Zinzadze* spray [34] [35]. M. p.: not corrected. ¹H-NMR: at 80 and 250 MHz: chemical shifts in δ [ppm] rel. to TMS.

2. *Phosphines. Dichloro(2-cyanoethoxy)phosphine* (la). To a soln. of PC1, (137.33 g, 85.5 ml, 1 mol) and dry pyridine (81 ml, 1 mol) in 200 ml of Et₂O under Ar at -78° was added dropwise within 90 min 3-hydroxypropanenitrile (71.05 g, 68 ml, 1 mol). After removal of cooling, stirring was continued overnight at r.t. The precipitate was removed by filtration under Ar and washed twice with 100 ml of Et₂O. After evaporation of Et₂O, the oily residue was dried for 3 h at 14 Torr, thereby obtaining 153 g (89%) of crude 1a. B.p. 95-100°/2 Torr. Since 1a decomposed partly during distillation, it was used as such for the preparation of **2a.**

(Benzy1oxy)dichlorophosphine **(Ib).** To a soln. of PC1, (13.73 g, 8.55 ml, 0.1 mol) and dry pyridine (8.1 ml, 0.1 mol) in 100 ml of dry Et,O under **Ar** was added benzyl alcohol (10.3 ml, 0.1 mol) in 50 ml of dry Et,O within 90 min at -78° . The precipitate was removed by filtration under Ar and washed twice with 100 ml of Et₂O. After evaporation of Et,O, the oily residue was bulb-to-bulb distilled, and 14.8 g (71 %) of **lb** were obtained as a colourless oil which is not very stable. Therefore, it was used directly for the preparation of **2b.**

(2-Cyanoethoxy)bis(diisopropylamino)phosphine (2a). To a soh. la of (37 g, 0.215 mol) in 300 ml of dry Et,O under Ar and stirring, $(i-Pr)$,NH (268 ml, 1.9 mol) was added within 1 h at -10° . Stirring was continued overnight at r.t. The precipitated hydrochloride was removed by filtration under Ar and washed twice with 100 ml of Et₂O. The combined Et₂O solns. were evaporated, and the oily residue was distilled after addition of 0.5 g of CaH₂ over a 10-cm *Vigreux* column under vacuum, whereby we obtained 40.3 g (64%) of pure **2a.** B.p. 117'/0.5 Torr. Anal. calc. for $C_{15}H_{32}N_3$ OP (301.42): C 59.77, H 10.70, N 13.94; found: C 59.69, H 10.53, N 13.96.

Benzyloxybis(diisopropy1amino)phosphine **(2b)** was prepared like **2a,** but starting from 70 mmol (14.6 g) of **lb** in 200 ml of Et₂O and 630 mmol (88 ml) of (i-Pr)₂NH. The crude 2b (95%) obtained after evaporation of Et₂O was used directly for the preparation of **3c.**

(p-Chlorobenzyloxy) (2-cyanoethoxy) *(diisopropy1amino)phosphine* **(3a).** To a soh. of 55 mmol(16.6 g) of **2a** and 25 mmol (4.30 g) of diisopropylammonium tetrazolide in 200 ml of CH₂Cl₂, 50 mmol (7.17 g) of p-chlorobenzyl alcohol were added under Ar and stirred. After complete addition, stirring was continued for another 2 h. The mixture was poured into 200 ml of sat. NaHCO₃ soln. which was then extracted 3 times with 100 ml of CH₂Cl₂. The combined org. layers were dried with $Na₂SO₄$ and evaporated. The oily residue was purified by short-column chromatography over 130 *g* of silica **gel** with CH,C1,/AcOEt/Et3N 80:15: 5: 16.1 g (94%) of **3a** as colourless oil. 'H-NMR (CDCI,): 1.18, 1.21 (2d, 2(CH3),CH); 2.63 *(t.* OCH,CH,CN); 3.55-3.95 (2m, OCH,CH,CN, 2(CH₃)₂CH); 4.55–4.80 *(m, C₆H₃CH₂)*; 7.30 *(br. s, C₆H₄)*. Anal. calc. for C₁₆H₂₄ClN₂O₂ (342.82): C 56.06, H 7.06, N 8.17; found: C 55.95, H 7.20, N 8.30.

Bis(2-cyanoethoxy) *(diisopropy1umino)phosphine* **(3b)** was prepared like **3a,** but starting from 40 mmol(17 g) of **2a** and 20 mmol(3.44 g) of diisopropylammonium tetrazolide in 200 ml of CH,CI, and 44 mmol (3.0 ml) of 3-hydroxypropanenitrile. After short-column chromatography of the crude material over 60 g of silica gel with 700 ml of Et₂O/pentane 3:1, we obtained 8.8 g (81%) of pure 3b as a colourless oil. ¹H-NMR (CDCI₁): 1.20 (d, 2(CH3),CH); 2.66 *(t,* 20CH2CH,CN); 3.58-3.68 *(m,* 2(CH3),CH); 3.78-3.94 *(m,* 2OCH,CH,CN). Anal. calc. for $C_{12}H_{22}N_2O_2P$ (271.30): C 53.13, H 8.17, N 15.46; found: C 53.03, H 8.23, N 15.49.

Bis(benzy1oxy) *(diisopropy1umino)phosphine* **(3c)** was prepared in the same way as **3a,** but starting from 65 mmol (22 g) of **2b** and 30 mmol (5.2 g) of diisopropylammonium tetrazolide in 150 ml of CH₂Cl₂ and 60 mmol (6.2 ml) of benzyl alcohol. The resulting crude oily material was purified by short-column chromatography over 60 **g** of silica gel with $CH_2Cl_2/ACOEt/Et_3N$ 80:15:5 and yielded 16 g (78%) of **3c** as a colourless oil. ¹H-NMR (CDCI₃): 1.23 *(d, 2(CH₃)₂CH)*; 3.45–4.05 *(m, 2(CH₃)₂CH)*; 4.81 *(d, 2C₆H₃CH₂)*; 6.90–7.20 *(m, 2C₆H₃)*. Anal. calc. for $C_{20}H_{28}NO_2P \cdot 0.1 \text{ CH}_2Cl_2 (353.92): C 68.21, H 8.03, N 3.96$; found: C 68.34, H 8.12, N 4.09.

3. Phosphorylation *of* a DNA Fragment *on* Solid Support via **5a** or **5b.** a) Phosphinylation and Oxidation. The DNA fragment d(TCCCATTCCCGAGGAGCT) was synthesized on controlled-pore glass as solid support using our standard procedure [29] [33]. The synthesis was started with 25 mg of functionalized support (0.67 mmol) and applying a soh of 10 mg of the corresponding (cyanoethy1)phosphoramidite and 6 mg of tetrazole in 250 **p1** of anh. MeCN for each elongation cycle (Table). The dimethoxytrityl protecting group at the 5'-end *of* this DNA fragment still attached in the completely protected form to the solid support was removed with 3 % CI,CHCOOH in dichloroethane [33]. Of this material, 10 mg were used for the phosphorylation with **3a** and 10 mg for the phosphorylation with **3b** using the phosphorylation cycle outlined in the Table. In each case we applied a soln. of 150 mg of **3a** or **3b** and 20 mg of tetrazole in 500 mg of anh. MeCN for the phosphorylation, and the oxidation was then performed with 0.2 M_2 in THF/lutidine/H₂O 2:1:2. The deprotection and purification was then performed according to b) or c).

b) Deprotection *of* **5a.** The support was treated with a mixture of thiophenol/dioxane/Et,N 1 : 2: 2 for 1.5 h. The mixture was filtered by suction into a soln. of I_2 in EtOH or 2.5% aq. NaOCl. The support was washed with dioxane, MeOH, THF, and Et,O, dried and then transferred to an Eppendorf tube. After addition of 700 **p1** of conc. $NH₃$ (at least 25%), the tightly closed tube was kept overnight at 56°. After removal of the support, the NH₃ soln. was evaporated on a speed-vac concentrator. The residue was taken up in 300 **pl** of AcOH and precipitated by addition of 700 μ l of Et₂O at r.t. After centrifuging, the pellet was dissolved in H₂O and part of this soln. was applied to gel electrophoresis on a 20% polyacrylamide gel. The bands of the product were visualized by UV shadowing (Fig. 1), eluted with H₂O, and desalted on small reversed-phase columns. In this way, we obtained the pure phosphorylated DNA fragment **6a.**

For identification, **the** fragment was ligated with DNA ligase and ATP [36] to a 25-mer DNA fragment and using a 30-mer DNA fragment as template and yielding the expected 43-mer. Since the enzyme can only link S'-phosphates of a DNA fragment to the 3'-end of another DNA fragment, this proved that the DNA fragment was really properly phosphorylated. The 43-mer DNA fragment obtained after ligation was then sequenced after labelling with $y-3^2P-ATP$ and polynucleotide kinase [36] using a modified Maxam-Gilbert procedure [30] [31] which confirmed the right sequence (data not shown).

c) Deprotection *of* **5b.** This was done in the same way as for **5a,** except that in a single deprotection step, treatment with 700 μ l of conc. NH₃ at 56° overnight gave directly the completely unprotected phosphorylated DNA fragment **6a** which was purified as in b) and identical with the product obtained in b).

4. N-Benzoyl- *04-[bis(benzyloxy)phosphino]-* L-tyrosine Benzyl Ester (Bz-Tyr(P(OBzl),)-OBzl; **4a).** To a soh. of 10 mmol(3.75 g) of Bz-Tyr-OBzl in 200 ml of anh. MeCN were added 20 mmol(1.40 g) of tetrazole and 11 mmol (3.80 **g)** of **3c** under Ar at r.t. and exclusion of moisture, whereupon a white precipitate was formed. Stirring was continued for 1 h, and then the mixture was poured into 200 ml of sat. NaHCO₁ soln. After extraction with CH₂Cl₂ $(3 \times 150 \text{ ml})$, the org. layers were dried over Na₂SO₄ and evaporated: 7.7 g of an oil. This material was then purified by short-column chromatography over 50 g of silica gel. The column was eluted with the following solvent mixtures: 300 ml of Et₂O/pentane 2: 3, 300 ml of Et₂O/pentane 1:1, and 300 ml of Et₂O/pentane 2:1. The pure fractions were collected (TLC: SiO₂, Et₂O, R_f 0.68) and evaporated. Crystallization of the residue from CH₂Cl₂/ Et₂O/pentane afforded 5.4 g of **4a** as colourless needles. A second crop afforded another 0.3 g. Yield: 5.7 g (92%) of **4a;** m.p. 90-91". In two other reactions starting from 3 mmol of Bz-Tyr-OBzl, the yield was 81%. 'H-NMR (CDCI,): 3.21 (d, *J* = 6, 2H-C(3)); 5.02 (d, *J* = 10, (C6H5CH20),P); 5.05-5.25 (ni, C,H,CH200, H-C(2)); 6.60 (br. d, NH); 6.95 (br. s, C_6H_4); 7.20–7.90 (m, $4C_6H_5$). Anal. calc. for $C_{37}H_{34}NO_6P$ (619.65): C 71.72, H 5.53, N 2.26; found: C 71.67, H 5.63, N 2.19.

5. Oxidations *of* **4a** *to N-Benzoyl-O4-[bis(benzyloxy)phosphoryl]-L-tyrosine* Benzyl Ester **(7a).** a) With tert-Butyl Hydroperoxide. To a soln. of 1 mmol (620 mg) of 4a in 50 ml of CH₂Cl₂, 2 mmol (0.29 ml) of tert-butyl hydroperoxide (70%; aq.) were added at r.t. and with stirring, whereupon the soln. turned yellow. Stirring was continued for 1 h when TLC showed complete disappearance of **4a** (silica gel, Et₂O, R_f 0.68). The mixture was poured into 50 ml of 10% NaHSO, soh. The org. layer was separated and the aq. layer extracted twice with 50 ml of CH₂Cl₂. The combined org. layers were dried with Na₂SO₄ and evaporated. The oily residue (650 mg) was purified by short-column chromatography on 10 g of silica gel using $Et_2O/pentane 2:1$. Two fractions were isolated in pure form. The first (450 mg; $R_f0.43$, silica gel, Et₂O) yielded, after crystallization from Et₂O/pentane, 325 mg (51%) of pure 7a. M.p. 84-85[°]. ¹H-NMR (CDCI₃): 2.74 (d, $J = 6$, 2H-C(3)); 5.05-5.30 *(m,* (C₆H₂CH₂O₂P, $C_6H_5CH_2OO$, H-C(2)); 6.66 (br. d, NH); 7.02 (br. s, C_6H_4); 7.30-7.90 (m, $4C_6H_5$). Anal. calc. for $C_{37}H_{34}NO_7P$ (635.65): C 69.91, H 5.39, N 2.20; found: C 69.69, H 5.36, N 2.11.

The 2nd fraction (110 mg; $R_f0.50$; silica gel, Et₂O) yielded, after crystallization, 80 mg (22%) of Bz-Tyr-OBzl.

b) With Iodobenzene Diacetate. To a soln. of 1 mmol (620 mg) of $4a$ in 50 ml of CH₂Cl₂, 2 mmol (640 mg) of iodobenzene diacetate were added at r.t. with stirring. Stirring was continued for 1 h, and then the mixture was poured into 50 ml of sat. NaHCO, soln. The org. layer was separated, and the aq. layer was extracted 4 times with 50 ml of CH,Cl,. The combined org. layers were collected and yielded, after evaporation, I. **1** g of an oil which was separated by short-column chromatography on silica gel (10 g) using 300 ml of pentane/Et₂O 1:2. The pure fractions were collected, and after evaporation and crystallization from $CH_2Cl_2/Et_2O/pentane$, 543 mg (86%) of pure **7a** were obtained, identical with a reference sample.

c) With Tetrabutylammonium Periodate. The reaction was carried out in the same way and with the same molar amounts as the oxidation with iodobenzene diacetate. TLC showed a complete reaction after 10 min. The mixture was evaporated and then purified by short-column chromatography over 10 g of silica gel using Et₂O. The pure fractions were collected and evaporated. Crystallization from pentane/CH₂Cl₂ yielded 520 mg (82%) of pure 7a, identical with a reference sample.

d) With m-Chloroperbenzoic Acid. To a soln. of 0.5 mmol (310 mg) of **4a** in 20 ml of CH₂Cl₂, 1 mmol (172 mg) of m -chloroperbenzoic acid was added at r.t. with stirring. Stirring was continued for 2 h. After dilution with another 20 ml of CH₂Cl₂, it was washed twice with a 10% NaHSO₃ soln., then with H₂O and finally with a sat. NaHCO₃ soln. The org. layer was dried over Na₂SO₄ and evaporated: 310 mg of an oil. Crystallization from CH2C12/pentane yielded **280** mg (89 %) of pure **7a,** identical with a reference sample.

e) With Peracetic Acid. To a soh. of I mmol(620 mg) of **4a** in 50 ml of CH,CI,, 2 mmol(0.35 ml) of peracetic acid were added at r.t. with stirring. Stirring was continued for 1 h. The mixture was poured into 50 ml of sat. NaHCO₃. The org. layer was separated and the aq. layer extracted 4 times with 50 ml of CH₂Cl₂. The combined org. layers were dried with Na,SO,, and after evaporation, 650 mg of colourless **7a** were obtained. Crystallization from $CH_2Cl_2/Et_2O/pentane$ yielded 605 mg (95%) of pure 7a.

6. One-pot Phosphorylations *of Amino* Acids. N-Benzoyl- *O4-[his(benzyIoxy)phosphoryl]-* L-tyrosine *Benzyl* Ester **(7a).** To a soln. of 1.2 mmol (448 mg) of Bz-Tyr-OBzl in 50 ml of anh. MeCN 2.4 mmol(170 mg) of tetrazole and 1.5 mmol(514 mg) of **3c** were added at r.t. with stirring. A few min after addition, a precipitate appeared. After 1 h, 1.7 mmol(290 mg) of m-chloroperbenzoic acid were added, whereupon the precipitate was dissolved. Stirring was continued for 1 h at r.t. Then, the mixture was taken up in 200 ml of Et₂O extracted 3 x with 5% aq. NaHSO₃ soln. (50 ml) and $3 \times$ with sat. NaHCO₃ soln. (50 ml), the Et₂O soln. dried with Na₂SO₄, and evaporated. The resulting oil was dissolved in 10 ml of Et_2O , and pentane was added until the soln. became slightly cloudy and the product started to crystallize. After filtration, the crystals were washed with pentane and dried: 735 mg (97%) of **7a,** m. p. 8&87", identical with **7a** obtained after oxidation of **4a.**

N-Benzoyl- 04-[(p-chlorobenzyloxy) *(2-cyanoethoxy)phosphoryl]-~-tyrosine* Benzyl Ester **(7b)** was synthetized like **7a** by the one-pot procedure from 1.2 mmol(448 mg) of Bz-Tyr-OBzl and 1.5 mmol (515 mg) of **3a.** The crude product, after evaporation of the org. layer, could not be crystallized and was, therefore, separated by short-column chromatography on 25 g of silica gel with 400 ml of $CH_2Cl_2/MeOH$ 99 : 1 and then 400 ml of CH2CI2/MeOH 98 : 2. The pure fractions yielded, after intensive drying of the residue, 725 mg (97%) of **7b** as an oil. ¹H-NMR (CDCI₃): 2.58–2.70 *(m, OCH₂CH₂CN)*; 3.12–3.34 (2dd, 2H–C(3)); 4.14–4.30 *(m, OCH₂CH₂CN)*; 5.05-5.30 *(m, CIC₆H₄CH₂O, C₆H₂CH₂O, H-C(2)); 6.62-6.70 (2 br. <i>d, NH)*; 6.94-7.05 *(m, C₆H₄); 7.24-7.78 <i>(m,* $2C_6H_5$). Anal. calc. for $C_{33}H_{30}CIN_2O_7P \cdot 0.1 \text{ CH}_2Cl_2 (641.53): C 61.97, H 4.75, N 4.57; found: C 61.51, H 4.97,$ N4.41.

N-Benzyloxycarbonyl- 03-[bis(benzyloxy)phosphoryI]- L-serine Methyl Ester **(8a)** was prepared like **7a** starting from 2 mmol (689 mg) of Z-Ser-OMe in 30 ml of anh. MeCN and 4 mmol (286 mg) of m-chloroperbenzoic acid. The resulting oil (1.3 g), after workup, was crystallized from 60 ml of pentane/Et₂O 5:1: 1.02 g (98%) of pure 8a, m.p. 91-92". 'H-NMR (CDCI,): 3.73 (s, CH30); 4.204.75 *(m,* H-C(2), 2H-C(3)); 5.05 (br. *d, J* = 8.8, 4H, $(C_6H_5CH_2O)$,P); 5.15 (br. s, $C_6H_5CH_2OCO$); 5.60-5.90 (br. *d*, NH); 7.41 (br. s, $3C_6H_5$). Anal. calc. for $C_{26}H_{28}NO_8P$ (513.48): C 60.82, H 5.50, N 2.73; found: C 60.68, H 5.59, N 2.67.

N-Benzyloxycarbonyl-O³-[(p-chlorobenzyloxy) (2-cyanoethoxy) phosphoryl]-L-serine Methyl Ester (8b) was prepared like **7b** starting from 4 mmol (1.09 g) of 2-Ser-OMe and **8** mmol (560 mg) of tetrazole in 100 ml of anh. MeCN to which were added 4.8 mmol (1.6 g) of 3a and 6 mmol (10.4 g) of m-chloroperbenzoic acid. Workup as for **7b** afforded 2.7 g of an oil. A first short-column chromatography over 50 g of silica **gel** using 500 ml of $CH_2Cl_2/MeOH$ 99:1, 500 ml of $CH_2Cl_2/MeOH$ 98: 2, and 500 ml of $CH_2Cl_2/MeOH$ 57: 3 yielded 1.42 g of pure 8b, and a second one on silica using the same solvent gradient but 250 ml instead of 500 ml yielded another batch of 0.48 g of 8b. Yield 1.90 g (93%). ¹H-NMR (CDCI₃): 2.59-2.70 (m, OCH₂CH₂CN); 3.76, 3.78 (2s, CH₃O); $(2d, NH)$; 7.25-7.48 *(m, C₆H₅, C₆H₄).* Anal. calc. for C₂₂H₂₄ClN₂O₈P (510.87): C 51.72, H 4.74, N 5.48; found: C 51.54, H 4.91, N 5.51. 4.05-4.63 (3 *m*, OCH₂CH₂CN, H-C(2), 2H-C(3)); 5.01, 5.05 (2d, ClC₆H₄CH₂); 5.12 (s, C₆H₂CH₂); 5.74, 5.82

N-Benzyloxycarbonyl-O3-[bis(benzyloxy)phosphoryI]- L-threonine Methyl Ester **(98)** was prepared like **8a** starting from 2 mmol(535 mg) of Z-Thr-OMe in 50 ml of MeCN and 4 mmol(280 mg) of tetrazole, 2.4 mmol(827 mg) of 3c and 2.5 mmol (430 mg) of m-chloroperbenzoic acid. The resulting oil (1.2 g) was purified by 3 short-column chromatographies on 20 g of silica gel each with CH₂Cl₂ and increasing amounts of MeOH (0.5-2%): total of 760 mg (72%) of pure **9a.** 'H-NMR (CDCI,): 1.36 *(d,* 3H-C(4)); 3.62 **(s,** CH30); 4.45 *(ddd,* Anal. calc. for $C_{27}H_{30}NO_8P$ (527.51): C 61.48, H 5.73, N 2.66; found: C 61.43, H 6.02, N 2.60. H-C(2)); 4.95-5.05 *(m, H-C(3), (C₆H₂CH₂O)P*); 5.13 *(s, C₆H₂CH₂O)*; 5.46 *(d, J* = 10, NH); 7.33 (br. *s*, 3C₆H₂).

N-Benzyloxycarbonyl-03-[(p-chlorobenzyloxy) (2-cyanoethoxy)phosphoryl]-~-threonine Methyl Ester **(9b)** was prepared like **9a** using 2.4 mmol(823 mg) of 3a: 1.3 **g** of crude **9b** as an oil. Purification was performed by short-column chromatography over 40 g of silica gel with 300 ml of CH₂Cl₂/MeOH 99:1 and 300 ml of CH₂Cl₂/ MeOH 98.5:1.5. The pure fractions (TLC) yielded 945 mg (90%) of **9b.** 'H-NMR (CDCI,): 1.38, 1.43 *(2d,* 3H-C(4)); 2.60-2.70 (2t, OCH₂CH₂CN); 3.70, 3.78 (2s, CH₃O); 4.05-4.15 *(m, OCH₂CH₂CN)*; 4.44, 4.51 *(ddd,* H-C(2)); 4.99-5.10 (2d, 1 m, ClC₆H₄CH₂OP and H-C(3), resp.); 5.14 (s, C₆H₅CH₂O); 5.55 (d, NH); 7.30-7.45 (m, C_6H_4 , C_6H_5). Anal. calc. for $C_{23}H_{26}CIN_2O_8P \cdot 0.1 \text{ CH}_2Cl_2$: C 52.02, H 4.95, N 5.25; found: C 51.87, H 5.17, N 5.35.

7. *Phosphorylation of Peptide* **10** *and its Transformation to P-DSIP* **15.** *B~c-Asp(OBzl)-Ala-Ser(PO(OBzl)~/- Gly-Giu(OBzl),* **(11).** To a soln. of 0.5 mmol (424 mg) of **10** in 70 ml of anh. MeCN, 1 mmol(70 mg) of tetrazole and 0.6 mmol (207 mg) of 3c were added at r.t. with stirring. Stirring was continued for 1 h, and then 0.8 mmol (140 mg) of m-chloroperbenzoic acid were added. After another h, the mixture was taken up in 100 ml of $Et₂O$ and extracted 3 times with 10% aq. NaHSO₃ soln. (30 ml). The org. layer was dried with Na₂SO₄ and then evaporated: 700 mg of oil. This was separated by short-column chromatography over 30 g of silica gel using 200 ml of CH_2Cl_2 , 200 ml of $CH_2Cl_2/MeOH$ 99:1, 200 ml of $CH_2Cl_2/MeOH$ 98:2, and 200 ml of $CH_2Cl_2/MeOH$ 97:3. The pure fractions (TLC: silica gel CHCI,/MeOH 19:1, *Rf* 0.44) gave 520 mg (94%) of **11** as an oil. This was precipitated from 100 ml of pentane/CH₂CI₂ 95: 5. The precipitate was collected by filtration, washed with pentane, and dried: 450 mg (81%) of **11** as a colourless powder. Anal. calc. for $C_{57}H_{66}N_5O_{16}P$ (1108.15): C 61.78, H 6.00, N 6.32; found: C 61.61, H 6.09, N 6.50.

Asp(OBzl)-Ala-Ser(PO(OBzl)2)-Gly-Glu(OBzl)2 **(12).** Compound **11** (1 mmol, 1.10 g) was treated for 5 min at r.t. with 15 ml of IN HCl/AcOH, and then the soln. was evaporated. The solid residue was taken up in 5 ml of DMF, adjusted with N-methylmorpholine to pH 8 and cooled to -20° .

Z-Trp-Ala-Gly-Gly-Asp(OBzl)-Ala-Ser(PO(OBzl)₂)-Gly-Glu(OBzl)₂(14). The mixed anhydride 13 was prepared *in situ* from 1.1 mmol(576 mg) of 2-Trp-Ala-Gly-Gly-OH [31] in 5 ml of DMF by adding 1.1 mmol(0.121 ml) of N-methylmorpholine, followed by 1.1 mmol (0.143 ml) of isobutyl chloroformate at -15° . After an activation time of 2 min at - 15", the DMF **soh.** of **12 (see** above) was added, and the soln. was kept for 10 min at -15° and 1 h at r.t. It was poured into 100 ml of 5% aq. NaHCO₃ soln. and the resulting precipitate was collected by filtration, washed with H20, dried, and crystallized from MeOH/hexane: 1.15 g (69%) of **14,** m.p. 221".

 $[\alpha]_D^{20} = -14.6^{\circ}$ (c = 1, DMF). Anal. calc. for $C_{78}H_{85}N_{10}O_{20}P$ (1513.56): C 61.90, H 5.66, N 9.25, P 2.05; found: C 61.70, H 5.79, N 9.40, P 2.08.

Trp-Ala-Gly-Gly-Asp-Ala-Ser(PO(OH)2)-Gly-Glu (15). In 20 ml of AcOH/H,O 4: 1,0.4 mmol(605 mg) of 14 were hydrogenated in the presence of 10% Pd/C. After complete uptake of H_2 , the catalyst was removed by filtration, and the soln. was evaporated. The residue was lyophilized once from $H₂O$ and then taken up in 5 ml of 0.2N AcOH and purified on a *DEAE-Sephadex* column (2.5 \times 6 cm) using a linear gradient of 0.5N AcOH (300 ml) and 300 ml of 0.8N HCOOH as solvent [37]. The fractions containing the pure product were lyophilized: 144 mg of pure 15. $[\alpha]_{0}^{20} = -19^{\circ}$ (c = 0.5, 1N AcOH). Amino-acid ratio: Trp 0.95, Asp 1.00, Ser 0.70, Glu 0.96, Gly 2.90, Ala 1.99. Anal. calc. for $C_{35}H_{49}N_{10}O_{18}P \cdot 4H_2O (1000.86)$: C 42.00, H 5.74, N 13.99; found: C 42.26, H 5.69, N 14.03.

REFERENCES

- [I] H. **J.** Lee, S.H. Moon, *Chem. Lett.* 1984, 1229.
- [2] S.L. Beaucage, *Tetrahedron Lett.* 1984,25, 375.
- [3] A. D. Barone, J. **Y.** Tang, M. H. Caruthers, *Nucleic Acids Res.* 1984, 12,4051.
- [4] M. F. Moore, **S.** L. Beaucage, *J. Org. Chem.* 1985,50,2019.
- [5] H. Boudjebel, H. Conqalves, F. Mathis, *Bull.* Soc. *Chim. Fr.* 1975,628.
- [6] J. Imai, P. F. Torrence, *J. Org. Chem.* 1981,46, 4015.
- [7] B. **J.** Hunt, W. Rigby, *Chem. Ind. (London)* 1967, 1868.
- **[S]** L. J. McBride, M. H. Caruthers, *Tetrahedron Lett.* 1983,24, 245.
- [9] N. D. Sinha, J. Biernat, H. Köster, *Tetrahedron Lett.* **1983**, 24, 5843.
- [lo] N. D. Sinha, J. Biernat, **J.** McManus, H. Koster, *Nucleic Acids Res.* 1984, 12, 4539.
- [I I] J. Engels, E. Uhlmann, *Tetrahedron Lett.* 1986, 1023.
- [I21 A. Beld, C. A.A. Claesen, E. **S.** Roersma, W. J. M. Schippers, L. M. Keizer, **C;.** I. Tesser, *Red. Trau. Chim.* Pays-Bas 1984, 103, 196.
- [I31 A.H. Beiter, W. Pfleiderer, *Tetrahedron Lett.* 1984,25, 1975.
- [14] C. Claesen, G. **I.** Tesser, C. E. Dreef, **J.** E. Marrugg, G. A. van der Marel, J. H. van Boom, *Tetrahedron Lett.* 1984,25, 1307.
- [15] *S.* Josephson, N. Balgobin, J. B. Chattopadhyaya, *Nucleic Acids Res. Symp. Ser.* 1981,9, 177.
- [I61 J. E. Marugg, N. Piel, L. W. Laughlin, M. Tromp, **G.** H. Veeneman, G.A. van der Marel, J. H. van Boom, *Nucleic Acids Res.* 1984, *12,* 8639.
- [17] F.R. Atherton, *Biochem. Prep.* 1957,5, **1.**
- [I81 S. M. Avaeva, M. M. Botvinik, **I.** F. Syromyatnikova, *Zh. Ohshch. Khim.* 1964,34, 1749.
- [I91 F. Folsch, *Sven. Kem. Tidskr.* 1967, 79, 38.
- [20] P. F. Alewood, J. W. Perich, R. B. Johns, *Ausi. J. Chem.* 1984,37,429.
- [21] R. L. Letsinger, W. B. Lunsford, *J. Am. Chem.* Soc. 1976,98, 3655.
- [22] J. G. Sharefkin, H. Saitzman, *Org. Synth.* 1963,43, 62.
- (231 A. Vargolis, *Chem. Soc. Rev.* 1981,10, 377.
- [24] J.L. Fourrey, J. Varenne, *Tetrahedron Lett.* 1985,26, 1217.
- [25] E. Santaniello, A. Manzocchi, C. Farachi. *Synthesis* 1980, 563.
- 1261 K. K. Ogilvie, M. J. Nemer, *Tetrahedron Lett.* 1981,22,2531.
- [27] K. Akashi, K., R. E. Palermo, K. B. Sharpless, *J. Org. Chem.* 1978,43,2063.
- [28] S. P. Adams, K. **S.** Kavkd, E. J. Wykes, **S.** B. Holder, G. R. Galluppi, *J. Am. Chem. Soc.* 1983, 105.661.
- [29] H. Kiefer, W. Bannwarth. in 'Methods in Immunology', Eds. I. Levkovits and B. Pernis, Academic Press, New York, 1985, Vol. **111,** pp. 69-83.
- [30] S.A. Chuvpilo, V.V. Kravchenko, *FEBS Lett.* 1985,179, 34.
- [31] V.G. Korobka, V.N. Dobrynin, I.V. Severtsova, N. **S.** Bystrov, S.A. Chuvpilo, M.N. Kolosov, *Nucleic Acids. Res. Symp. Ser.* 1980, 7, 365.
- [32] E. Wunsch, Ed., 'Houben-Weyl-Muller, Methoden der organischen Chemie', Thieme, Stuttgart, 1974, Vol. 15, Part I.
- [33] W. Bannwarth, P. Iaiza, *DNA* 1986, 5, 413.
- [34] C. Zinzadze, *Ind. Eng. Chem.* 1935, 7,227.
- [35] J. C. Dittmer, R. L. Lester, *J. Lipid Res.* 1964, 5, 126.
- [36] T. Maniatis, in 'Molecular Cloning', 1982, Cold Spring Harbor Laboratory, New York.
- [37] D. Gillessen, private communication *(F. HoJfmann-La Roche* & Co., *Ltd.,* Basel).